secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2026-05-13T20:16:30+00:00
Accession:  0001689548-26-000049
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis reports Q1 net loss of $92.6M; FDA accepts NDAs for ulixacaltamide and relutrigine
--------------------------------------------------------------------------------

- FDA accepted NDA for ulixacaltamide (Essential Tremor) with PDUFA Jan 29, 2027; relutrigine NDA (SCN2A/SCN8A DEEs) granted priority review with PDUFA Sept 27, 2026.
- Cash and investments $1.4B as of Mar 31, 2026, up from $926.1M Dec 2025; funded into 2028.
- Net loss $92.6M vs $69.3M in Q1 2025; R&D expenses $78.0M (up $17.2M YoY); G&A $27.9M (up $14.0M YoY).
- EMBRAVE Part A: elsunersen showed 77% placebo-adjusted seizure reduction; 71% patients achieved >50% reduction.
- Topline POWER1 (vormatrigine in FOS) expected Q2 2026; EMERALD (relutrigine in broad DEEs) topline Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/0001689548-26-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/prax-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001689548-26-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer